Woodline Partners’s Kyntra Bio KYNB Stock Holding History

Woodline Partners’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,644	Closed	-$6.27M	–	686
2022 Q4	$6.27M	Buy	+15,644	New	+$5.99M	0.08%	282

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Woodline Partners's KYNB Position: Q1 2023 in Review

Woodline Partners sold out of Kyntra Bio (KYNB) in Q1 2023, closing a stake of 15,644 shares — an estimated $6.27M sold.

Woodline Partners first reported a position in KYNB in Q4 2022 and held it in 1 quarter. The position peaked at $6.27M in Q4 2022. 171 funds tracked by Wall St. Rank hold KYNB as of Q1 2023.

Woodline Partners reported no remaining Kyntra Bio position as of Q1 2023 after selling out during the quarter.
Woodline Partners sold 15,644 Kyntra Bio shares in Q1 2023, an estimated $6.27M.
Woodline Partners first reported a position in Kyntra Bio in Q4 2022 and held it in 1 quarter.
Woodline Partners's Kyntra Bio position peaked at $6.27M in Q4 2022.
171 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2023.

Based on Woodline Partners's 13F filing for Q1 2023, filed 15 May 2023.